A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. (Q33391296)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694830%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

title

A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694830%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694830%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Michele Caraglia

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694830%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Liliana Montella

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694830%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Bruno Vincenzi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694830%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

M Serena De Santi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694830%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Alberto Abbruzzese

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694830%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Ciro Parlato

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694830%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Marco Carraturo

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694830%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Vincenzo Faiola

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694830%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Michele Genovese

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694830%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Gregorio Cennamo

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694830%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Salvatore Del Prete

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694830%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

publication date

10 August 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694830%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

number of pages

8

1 reference

Journal of Neuro-Oncology

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694830%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

102

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694830%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

417-424

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694830%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694830%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11060-010-0329-z

9 February 2020

exact match

0 references

cites work

Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089727

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089727

Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089727

Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089727

Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089727

Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089727

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089727

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089727

Therapeutic options for recurrent high-grade glioma in adult patients: recent advances

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089727

Changing paradigms--an update on the multidisciplinary management of malignant glioma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089727

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089727

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089727

A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089727

Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089727

Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089727

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089727

Fotemustine (Muphoran) in 22 patients with relapses of high-grade cerebral gliomas

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089727

Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089727

Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089727

Comparative diffusion study of two nitrosoureas: carmustine and fotemustine in normal rat brain, human and rat brain biopsies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089727

Phase II study of fotemustine in recurrent supratentorial malignant gliomas

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089727

Fotemustine and recurrent glioblastoma: possible new opportunities for an old drug.

21 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0329-Z

A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0329-Z

Inhibition of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0329-Z

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0329-Z

Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0329-Z

Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0329-Z

Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0329-Z

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0329-Z

Treatment of recurrent high grade astrocytoma; results of a systematic review of 1,415 patients.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089727

Response criteria for phase II studies of supratentorial malignant glioma

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089727

One-sample multiple testing procedure for phase II clinical trials

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20694830

12 December 2020

inferred from PubMed ID database lookup

Antitumor activity of the novel nitrosourea S10036 in rodent tumors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20694830

12 December 2020

inferred from PubMed ID database lookup

In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20694830

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S11060-010-0329-Z

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694830%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

9 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20694830%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference